Atrial Fibrillation Detected by Continuous ECG Monitoring

NACompletedINTERVENTIONAL
Enrollment

6,000

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

February 29, 2020

Study Completion Date

March 31, 2021

Conditions
Atrial FibrillationStrokeHypertensionDiabetes
Interventions
DEVICE

Implantable loop recorder (Medtronic Reveal LINQ(TM))

The patients in the experimental arm receive an implantable loop recorder (Medtronic Reveal LINQ(TM)) with continuous monitoring, and are followed by daily automated remote transmissions. New arrhythmia episodes are reviewed daily by an experienced medical doctor. If AF lasting ≥6 minutes is detected and confirmed by at least two senior cardiologists, OAC is initiated. Decision about specific type of OAC, and possible further clinical work-up or treatment, is left to the treating physician and the patient. The remote monitoring continues until end of service of the device, patient withdrawal or other end-of-study.

Trial Locations (1)

Unknown

Rigshospitalet, Copenhagen

All Listed Sponsors
collaborator

Bispebjerg Hospital

OTHER

collaborator

Zealand University Hospital

OTHER

collaborator

Odense University Hospital

OTHER

collaborator

University of Southern Denmark

OTHER

collaborator

Aalborg University

OTHER

lead

Rigshospitalet, Denmark

OTHER

NCT02036450 - Atrial Fibrillation Detected by Continuous ECG Monitoring | Biotech Hunter | Biotech Hunter